October 2008

► NEW DRUGS	Standard Plan	Select Plan	Closed Plan
No new drugs were reviewed at the September meeting.

► LINE EXTENSIONS	Standard Plan	Select Plan	Closed Plan
Requip XL (ropinirole)
Indicated for the treatment of Parkinsons disease. New dose form reviewed. In a limited category (anti-Parkinsons)	Brand copay.	Second tier, preferred brand copay.	Second tier, preferred brand copay.
Asmanex 110 mcg (mometasone furoate inhalation powder)
A corticosteroid indicated for the treatment of asthma as prophylactic therapy in patients 4 years of age and older. New strength reviewed. In a limited category (asthma/COPD) Quantity Limit (QL)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Atacand-HCT 32/25mg (candesartan-hctz)
The combination of an angiotensin II receptor antagonist (ARB) and a diuretic used in the treatment of hypertension. New tablet strength reviewed. In a limited category (blood pressure - ARBs) DACON edits apply	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► DRUG CLASS REVIEW 5-HT1 Receptor Agonists	Standard Plan	Select Plan	Closed Plan
Imitrex, Relpax, Zomig
Full class review 5-HT1 receptor agonists, also known as "triptans", used in the acute treatment of migraine attacks. In a limited category (migraine) Quantity Limit (QL) There were no changes to this category.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Amerge, Axert, Frova, Maxalt, Treximet
Full class review 5-HT1 receptor agonists, also known as "triptans", used in the acute treatment of migraine attacks. In a limited category (migraine) Quantity Limit applies There were no changes to this category.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► DRUG CLASS REVIEW Multiple Sclerosis Agents	Standard Plan	Select Plan	Closed Plan
Betaseron, Copaxone, Rebif
Full class review of agents to treat multiple sclerosis (MS). In a limited category (multiple sclerosis) Prior authorization (PA) Specialty Pharmacy Program There were no changes to this category.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.
Novantrone
Full class review of agents to treat multiple sclerosis (MS). In a limited category (multiple sclerosis) Specialty Pharmacy Program There were no changes to this category.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.
Avonex
Full class review of agents to treat multiple sclerosis (MS). In a limited category (multiple sclerosis) Prior Authorization (PA) Specialty Pharmacy Program Step Therapy There were no changes to this category.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the third tier, non-preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	Not covered.
Tysabri
Full class review of agents to treat multiple sclerosis (MS). In a limited category (multiple sclerosis) There were no changes to this category.	Not covered by the pharmacy benefit. May be considered under the medical benefit.	Not covered by the pharmacy benefit. May be considered under the medical benefit.	Not covered by the pharmacy benefit. May be considered under the medical benefit.

► DRUG CLASS REVIEW TNF Antagonists	Standard Plan	Select Plan	Closed Plan
Enbrel, Humira
Class review of TNF antagonists. Individual agents may be approved for treatment of one or more of the following indications: psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. Limited category (TNF antagonists) Prior Authorization (PA) Specialty Pharmacy Program Quantity Limit (QL) Rx Instep (psoriasis)	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.
Remicade
Class review of TNF antagonists. Individual agents may be approved for treatment of one or more of the following indications: psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. Limited category (TNF antagonists) Specialty Pharmacy Program	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the second tier, preferred brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.
Cimzia
Class review of TNF antagonists. Individual agents may be approved for treatment of one or more of the following indications: psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. Limited category (TNF antagonists) Prior Authorization (PA) Specialty Pharmacy Program	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the third tier, non-preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	Not covered.

► DRUG CLASS REVIEW HMG-CoA Reductase Inhibitors	Standard Plan	Select Plan	Closed Plan
lovastatin, pravastatin, simvastatin
Class review of HMG-CoA reductase inhibitor ("statin") medications used in the treatment of hyperlipidemia. In a limited category (cholesterol lowering) DACON edits apply	Generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.
Advicor, Caduet, Crestor, Lipitor, Vytorin
Class review of HMG-CoA reductase inhibitor ("statin") medications used in the treatment of hyperlipidemia. In a limited category (cholesterol lowering) DACON edits apply	Brand copay . Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Altoprev, Lescol / XL, Mevacor, Pravachol, Zocor
Class review of HMG-CoA reductase inhibitor ("statin") medications used in the treatment of hyperlipidemia. In a limited category (cholesterol lowering) DACON edits apply	Brand copay, Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► PPL UPDATES	Standard Plan	Select Plan	Closed Plan
Locoid Lipocream
A potent topical corticosteroid that is applied to the skin to treat severe inflammatory skin disorders, such as eczema and psoriasis, that have not responded to milder steroids. Removed from preferred status, effective December 1, 2008.	Brand copay.	Third tier, non-preferred brand copay.	Not covered.
Pristiq (desvenlafaxine SR tab)
Indicated for the treatment of major depressive disorder (MDD) in adults. Added to the Preferred Product List (PPL), effective October 1, 2008. In a limited category (antidepressants - SNRI type) DACON edit	Brand copay. Coverage limits determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage limits determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage limits determined by the benefit design chosen by the plan sponsor.

► BRANDS WITH GENERICS AVAILABLE	Standard Plan	Select Plan	Closed Plan
Risperdal (risperidone)
An atypical antipsychotic used for the treatment of schizophrenia, bipolar mania, and irritability associated with autistic disorder. Removed from preferred status because the generic equivalent, risperdone, is available at the generic copay.	Brand copay.	Third tier. non-preferred brand copay.	Not covered.

► CLINICAL PROGRAMS	Standard Plan	Select Plan	Closed Plan
Amitiza (lubiprostone)
Indicated for the treatment of chronic idiopathic constipation. Added to the DACON program.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Chantix (varenicline)
Indicated as an aid to smoking cessation treatment. Non-standard category (smoking cessation) Added to the DACON program.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Sonata (zaleplon)
Indicated for the short-term treatment of insomnia. Added to the DACON program.	Sonata : Brand copay. zaleplon: generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	Sonata : Brand copay. zaleplon: generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	Sonata: not covered. zaleplon: first tier, generic copay
Omnaris (ciclesonide nasal susp)
Indicated for the treatment of nasal symptoms of seasonal allergic rhinitis (SAR) in patients ≥ 6 years of age and for perennial allergic rhinitis (PAR) in patients for ≥ 12 years of age. In a limited category (allergy - intranasal) Added to the Quantity Limits program.	Brand co-pay. Coverage limits determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred copay. Coverage limits determined by the benefit design chosen by the plan sponsor.	Not covered.

	October 2008



Innoviant's Business Committee meets monthly to evaluate product status (tier placements) and new prescription products approved by the Food and Drug Administration (FDA). Decisions made by the Innoviant Business Committee are based on information and recommendations provided by Prescription Solutions' National Pharmacy & Therapeutics Committee (NPTC). The P&T is comprised of independent physician providers, affiliated plan physicians and pharmacists. The following table summarizes the decisions made at the September committee meetings. Additions to the Preferred Products List (PPL) are effective immediately. All other changes are effective December 1 unless otherwise noted. Current information related to Innoviant and its offerings is available at http://www.innoviant.com/. A copy of this newsletter can also be found on the website.